[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Iran\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":702},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,69,0,25,[9,47,82,109,144,166,199,230,257,288,316,337,376,407,428,448,468,488,519,549,576,597,632,656,680],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":7},"100579387","an-international-multicenter-study-on-transcatheter-device-closure-of-perimembranous-ventricular-septal-defects-100579387",false,"NCT06823635","An International Multicenter Study on Transcatheter Device Closure of Perimembranous Ventricular Septal Defects","PERI-CLOSE","Inclusion Criteria:\n\n1. Patients with perimembranous ventricular septal defects (PmVSD) diagnosed by 2D transthoracic echocardiography according to established classification systems, who provided informed consent and underwent transcatheter closure using any commercially available occluder devices (whether specifically designed for this indication or used off-label), with follow-up according to local hospital protocols.\n2. Defect size between 3 mm and \\\u003C20 mm on the left ventricular side, as measured by 2D echocardiography.\n3. Age ≥1 month and body weight ≥5 kg.\n4. Left-to-right ventricular shunt.\n\nExclusion Criteria:\n\n1. Patients or legal guardians refusing the use of personal data for research purposes.\n2. Failure to attend any follow-up visit post-discharge.","ALL","1 Month",{"count":20,"type":21},2000,"ESTIMATED","OBSERVATIONAL","The international multicenter registry aims to gather real-world data on patient outcomes and assess the procedural success and performance of various device occluders used in the transcatheter treatment of pediatric and adult patients with perimembranous ventricular septal defects (PmVSD).",[25],"Perimembranous Ventricular Septal Defect",[27,28,29,30,31,32,33,34],"Cardiovascular Abnormalities","Congenital Heart Disease","Device Closure","Heart Defects, Congenital","Heart Septal Defects","Heart Septal Defects, Ventricular","Transcatheter Interventions","Ventricular Septal Defects","RECRUITING","2026-08-24",{"date":38,"type":39},"2026-08-25","ACTUAL",{"date":41,"type":39},"2025-01-01",{"date":43,"type":21},"2027-06-30",{"name":45,"class":46},"Fondation Hôpital Saint-Joseph","OTHER",{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100653136","brain-stimulation-with-combined-reading-and-motor-training-for-children-with-dyslexia-100653136","NCT07781761","Brain Stimulation With Combined Reading and Motor Training for Children With Dyslexia","Effectiveness of Dual-Site tDCS Combined With Integrated Phonological and Fine Motor Intervention in 9-Year-Old Boys With Developmental Dyslexia: A Randomized, Double-Blind, Sham-Controlled Trial","Inclusion Criteria:\n\n* Male children aged 9 years (9 years 0 months to 9 years 11 months) with developmental dyslexia diagnosed according to DSM-5 criteria by a clinical team.\n* Reading and Dyslexia Test (NAMA) T score ≤ 30 (at least 2 standard deviations below the mean).\n* Full Scale IQ ≥ 85 on the Wechsler Intelligence Scale for Children, Fifth Edition (WISC-V).\n* Score below 88 on the Spence Children's Anxiety Scale (SCAS).\n* Fine motor deficits defined as standard score ≤ 40 on Bruininks-Oseretsky Test of Motor Proficiency, Second Edition (BOT-2) manual dexterity and upper-limb coordination subtests.\n* Normal or corrected-to-normal vision and hearing.\n* No history of seizure or epilepsy, no scalp skin disease, no cochlear implant, cardiac pacemaker, or metal implants in the skull.\n* Written informed consent from parents or legal guardian and verbal assent from the child.\n\nExclusion Criteria:\n\n* Intellectual disability (Full Scale IQ \\\u003C 85).\n* Personal history of epilepsy or seizure disorder, or epilepsy in a first-degree relative.\n* Presence of cochlear implant, cardiac pacemaker, or metal implants in the skull.\n* Skin diseases or open lesions on the scalp at electrode sites.\n* Uncorrected visual or hearing impairments.\n* Other primary psychiatric or neurodevelopmental disorders requiring ongoing treatment (e.g., ADHD, autism spectrum disorder, severe anxiety disorder).","MALE","108 Months","119 Months",{"count":58,"type":21},160,"INTERVENTIONAL",[61],"NA","This study examines whether combining non-invasive brain stimulation (tDCS) with an integrated reading-and-motor training program improves reading and phonological processing in 9-year-old boys with developmental dyslexia.\n\nChildren with dyslexia often have difficulties in phonological awareness and fine motor skills. This study targets two brain areas at the same time: the left temporoparietal junction (important for reading and phonological processing) and the left primary motor cortex (important for hand movements and speech-related motor processes).\n\nParticipants will be randomly assigned to one of eight groups. Some groups will receive active brain stimulation, and some will receive sham (inactive) stimulation, while also participating in different types of training: phonological awareness training, fine motor training, combined phonological and fine motor training, or no training. The treatment includes 20 sessions, three times per week for about 7 weeks.\n\nReading and phonological skills will be measured before treatment, immediately after treatment, and again 3 months and 6 months later. The study will help determine whether a full treatment package-using brain stimulation together with combined reading and motor training-is more effective than single treatments or usual school education.",[64],"Developmental Dyslexia",[64,66,67,68,69,70,71],"tDCS","Phonological Awareness","Fine Motor Training","Reading","Children","Dual-site transcranial direct current stimulation","NOT_YET_RECRUITING","2026-08-21",{"date":38,"type":39},{"date":76,"type":21},"2026-08-23",{"date":78,"type":21},"2027-08-01",{"name":80,"class":46},"Shahid Beheshti University",1,{"id":83,"slug":84,"hasResults":12,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":12,"sex":54,"minAge":89,"maxAge":4,"enrollmentInfo":90,"targetDuration":92,"studyType":22,"phases":4,"briefSummary":93,"conditions":94,"keywords":97,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":108},"100480992","bph-global-registry-100480992","NCT05543200","BPH Global Registry","A Global Registry of Treatments and Outcomes for Benign Prostatic Hyperplasia","Inclusion Criteria:\n\n* Primary diagnosis of BPH with LUTS with prescribed medical treatment or surgical intervention\n\nExclusion Criteria:\n\n* Non-symptomatic BPH\n* No treatment prescribed for BPH","18 Years",{"count":91,"type":21},7500,"3 Years","Benign prostatic hyperplasia (BPH) is one of the most common performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been standardized. While data are available for the initial pivotal studies, post-market release data are lacking. Under the umbrella of uCARE, we have started a prospective, ongoing international registry for recording demographics and outcomes for patients undergoing surgical treatments for BPH.",[95,96],"Benign Prostatic Hyperplasia","Lower Urinary Tract Symptoms",[98],"BPH, Registry, LUTS","2026-08-11",{"date":101,"type":39},"2026-08-13",{"date":103,"type":39},"2023-03-13",{"date":105,"type":21},"2028-12",{"name":107,"class":46},"Société Internationale d'Urologie",30,{"id":110,"slug":111,"hasResults":12,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":12,"sex":17,"minAge":89,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":59,"phases":120,"briefSummary":121,"conditions":122,"keywords":132,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":81},"100649789","the-effects-of-5-methyltetrahydrofolate-supplementation-in-patients-with-metabolic-dysfunction-associated-steatotic-liver-disease-100649789","NCT07740109","The Effects of 5-methyltetrahydrofolate Supplementation in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease","The Effect of 5-methyltetrahydrofolate Supplementation on Serum Folate and Homocysteine Level and PPARα and TNFα Gene Expression in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: a Double-blind, Parallel Randomized Controlled Trial Study","MASLD","Inclusion Criteria:\n\n* Adult men or women (18-50 years)\n* Diagnosis of MASLD (grade 1 or 2 of steatosis confirmed by ultrasound)\n* Body mass index (BMI) = 25-34.9 kg\u002Fm²\n* Providing written informed consent\n\nExclusion Criteria:\n\n* Pregnancy, lactation, or plans to get pregnant during the next three months.\n* Liver disease (viral hepatitis, autoimmune liver disease, cirrhosis, drug-induced hepatotoxicity, or alcoholic fatty liver disease), heart or renal failure, kidney stones, any neoplasia, inflammatory disease, hypothyroidism, hypercortisolism, or hypertension\n* Taking drugs affecting glucose or lipid metabolism, folate supplements, anti-obesity medications, weight-loss diets, or dietary supplements\n* Lifestyle factors known to impact folate status (current smoking, alcohol intake, recreational drug use)\n* Pre-existing conditions affecting folate status (malabsorptive or inflammatory bowel diseases, active celiac disease, gastric bypass surgery, atrophic gastritis, epilepsy, advanced liver disease, kidney dialysis, type 1 or 2 diabetes mellitus, or sickle cell trait\u002Fanemia)\n* Medications that interfere with B-vitamin metabolism (chloramphenicol, methotrexate, metformin, sulfasalazine, phenobarbital, phenytoin, primidone, triamterene, barbiturates)","50 Years",{"count":119,"type":21},44,[61],"To determine the effect of MTHF supplementation on serum folate and homocysteine level, metabolic, nutritional status, liver function, and PPARα and TNFα gene expression in patients with MASLD",[123,124,125,115,126,127,128,129,130,131],"Nonalcoholic Fatty Liver Disease","Nonalcoholic Fatty Liver Disease (NAFLD)","MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","NAFLD","Metabolic Dysfunction-Associated Steatotic Liver Disease","NAFLD (Nonalcoholic Fatty Liver Disease)","NAFLD (Non-alcoholic Fatty Liver Disease)","NAFLD - Non-Alcoholic Fatty Liver Disease","NAFLD - Nonalcoholic Fatty Liver Disease",[133,134,115,126,123,127],"5-methyltetrahydrofolate","homocysteine","2026-07-30",{"date":137,"type":39},"2026-07-31",{"date":139,"type":21},"2026-09-30",{"date":141,"type":21},"2027-08-30",{"name":143,"class":46},"Tabriz University of Medical Sciences",{"id":145,"slug":146,"hasResults":12,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":12,"sex":17,"minAge":89,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":59,"phases":154,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":81},"100563176","naringenin-supplementation-in-bone-fracture-patients-100563176","NCT06612762","Naringenin Supplementation in Bone Fracture Patients","Effect of Naringenin Supplementation on the Speed of Bone Fusion and the Concentration of Plasma Inflammatory Factors in Patients With Bone Fractures.","Inclusion Criteria:\n\n* Candidate for orthopedic surgery for bone fractures of the lower limbs,\n* Ambulatory without assistance for a minimum of two months prior to the fracture.\n* Not having undergone amputation of the lower limbs.\n* Not suffering from liver cirrhosis.\n* Not suffering from advanced kidney failure (blood creatinine higher than 1.4 mg\u002FdL).\n* Not having metastatic cancer, any chronic inflammatory diseases, nor taking any drugs that affect bone metabolism, including calcitonin, bisphosphonates, and corticosteroids.\n\nExclusion Criteria:\n\n* Allergy or intolerant reaction to narangenin capsules\n* Any abnormal changes in their liver, kidneys tests,\n* Failure to consume more than 10% of their capsules","60 Years",{"count":153,"type":21},70,[61],"Fractures of the lower extremities represent a significant proportion of injuries sustained by polytrauma patients, with a notable association with prolonged hospitalization, chronic disability, and impaired physical functioning. The occurrence of surgical site infections (SSI) represents a significant threat to the efficacy of osteosynthesis procedures. As with other traumas and surgical procedures, the secretion of inflammatory mediators is markedly elevated in this cohort of patients following surgery. Naringenin is one of the most prevalent flavonoids, occurring naturally in grapefruit and other citrus fruits. In vitro studies have demonstrated that naringenin may stimulate the release of osteogenic cytokines and suppress the production of pro-inflammatory factors, which can result in a reduction in bone resorption. Based on these findings, naringenin may prove an effective agent for accelerating the rate of fusion and controlling inflammation. Furthermore, it may enhance quality of life and augment functional activity.",[157],"Bone Fractures","2026-07-29",{"date":135,"type":39},{"date":161,"type":39},"2024-11-03",{"date":163,"type":21},"2026-11-02",{"name":165,"class":46},"Shahid Beheshti University of Medical Sciences",{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":12,"sex":17,"minAge":89,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":59,"phases":176,"briefSummary":177,"conditions":178,"keywords":181,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":81},"100648216","the-effect-of-intradialytic-exercise-on-postural-abnormalities-100648216","NCT07720401","The Effect of Intradialytic Exercise on Postural Abnormalities","Effects of Supervised Intradialytic Exercise Program on Postural Abnormalities in Maintenance Hemodialysis Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 18-80 years\n* Diagnosed with ESRD and receiving stable maintenance hemodialysis for at least 3 months at the participating center, with a dialysis frequency of three sessions per week\n* Confirmed presence of at least one postural abnormality (hyperkyphosis ≥53° in women or ≥55° in men, or CVA \\\u003C53°) assessed at screening\n* Written informed consent obtained, indicating decision-making capacity and willingness to participate\n* Medical clearance from attending nephrologist to participate in supervised exercise during dialysis\n* Ability to sit upright in a dialysis chair and perform seated or supported standing exercises\n* Ability to communicate in Persian and understand study instructions\n\nExclusion Criteria:\n\n* Unstable cardiovascular status, including recent (within 3 months) myocardial infarction, unstable angina, decompensated congestive heart failure (NYHA Class III-IV), or uncontrolled arrhythmia\n* Active infection, acute febrile illness, or acute medical condition requiring hospitalization\n* Hemodynamic instability defined as systolic blood pressure \\\u003C90 mmHg or \\>200 mmHg, or severe orthostatic hypotension, at screening or prior to exercise sessions\n* Uncontrolled diabetes mellitus with labile glycemic control (blood glucose \\\u003C4 mmol\u002FL or \\>22 mmol\u002FL at dialysis session start)\n* Severe musculoskeletal pain at rest or with minimal activity (Numeric Pain Rating Scale ≥7\u002F10) that would preclude exercise participation\n* Inability to perform seated exercises, walk independently, or maintain upright posture; severe neurological disability\n* Recent fracture (within 6 months) of vertebral column, pelvis, or lower extremities\n* Severe peripheral neuropathy or vascular disease (ABI \\\u003C0.6) precluding lower limb exercise\n* Dyspnea at rest or with activities of daily living corresponding to NYHA Class IV\n* Participation in a structured exercise program targeting postural correction, resistance, or balance training ≥3 times per week in the preceding 3 months\n* Severe cognitive impairment (MMSE \\\u003C18) preventing informed consent or adherence to exercise instruction\n* Pregnancy or planned pregnancy during the study period\n* Life expectancy \\\u003C6 months as determined by the attending nephrologist\n* Scheduled kidney transplantation within the study period","80 Years",{"count":175,"type":21},98,[61],"This randomized, assessor-blinded controlled trial will evaluate the preliminary efficacy and safety of a 12-week supervised intradialytic multimodal exercise program for improving postural abnormalities in adults receiving maintenance hemodialysis. Participants will be randomized to either supervised intradialytic exercise plus usual care or usual care alone. The exercise program will be performed three times per week during scheduled hemodialysis sessions and will include postural correction exercises, resistance-band strengthening, core stabilization, stretching, breathing exercises, and seated aerobic cycling. The primary outcome will be change in thoracic kyphosis angle from baseline to Week 12. Secondary outcomes will include craniovertebral angle, balance, mobility, functional exercise capacity, gait speed, physical activity level, adherence, and adverse events. The findings may provide preliminary evidence on the feasibility, safety, and potential clinical value of incorporating postural correction exercises into routine hemodialysis care.",[179,180],"End-Stage Renal Disease","Hemodialysis Complication",[182,183,184,185,186,187,188,189],"Intradialytic Exercise","Hemodialysis","Postural Abnormalities","Hyperkyphosis","Forward Head Posture","Balance","Physical Function","Quality of Life","2026-07-24",{"date":192,"type":39},"2026-07-27",{"date":194,"type":21},"2026-07-25",{"date":196,"type":21},"2026-11",{"name":198,"class":46},"Pardis Specialized Wellness Institute",{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":12,"sex":17,"minAge":89,"maxAge":173,"enrollmentInfo":206,"targetDuration":4,"studyType":59,"phases":208,"briefSummary":210,"conditions":211,"keywords":213,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":81},"100647514","early-phase-1-safety-and-feasibility-of-cik-cell-therapy-in-hcc-after-tumor-resection-100647514","NCT07709299","Safety and Feasibility of CIK Cell Therapy in HCC After Tumor Resection","Safety and Feasibility of Autologous Cytokine Induced Killer (CIK) Cells Infusion as an Adjuvant Therapy in Post Resection Hepatocellular Carcinoma (HCC) Patients","Inclusion Criteria:\n\n* Age between 18 and 80 years\n* Documented HCC at BCLC stage 0-A, having undergone surgical tumor resection\n* Single tumor or ≤3 nodules, each ≤3 cm\n* Child-Pugh score A-B\n* ECOG performance status 0-1\n* Confirmed cancer-free status one month after surgery\n* Written informed consent\n* Leukocyte count \\> 3 × 10⁹\u002FL\n* Absolute neutrophil count (ANC) ≥ 1,000\u002FµL\n* Hemoglobin ≥ 8.5 g\u002FdL\n* Platelet count \\> 50 × 10⁹\u002FL\n* BUN and serum creatinine ≤ 1.5 × upper limit of normal No extrahepatic abdominal disease spread, confirmed by abdominal CT\u002FMRI\n\nExclusion Criteria:\n\n* Active infection or uncontrolled viremia (particularly HBV, HCV, or HIV)\n* Any cell therapy or immunotherapy in the past 6 months, or current participation in another clinical study\n* Another malignancy (prior or concurrent) differing from HCC in primary site or histology\n* Clinically significant cardiovascular disease (e.g., heart failure, serious arrhythmia, symptomatic coronary artery disease)\n* History of organ transplantation\n* Primary or secondary immunodeficiency, or active autoimmune disease\n* Severe allergic disorder or history of anaphylaxis\n* Pregnancy or breastfeeding at study entry\n* Women of childbearing potential intending to become pregnant",{"count":207,"type":21},6,[209],"EARLY_PHASE1","This study tests whether it is safe and feasible to give patients with hepatocellular carcinoma (liver cancer) an infusion of their own (autologous) immune cells, called cytokine-induced killer (CIK) cells, after they have had surgery to remove their liver tumor. The patient's own blood cells are collected and grown in a laboratory to create the CIK cells, which are then given back to the patient through six intravenous infusions over about two months. Patients are followed for six months to check for side effects and early signs of whether the cancer returns.",[212],"Hepatocellular Carcinoma (HCC)",[214,215,216,217,218,219],"Cytokine-induced killer cell","CIK Cells","Hepatocellular carcinoma","HCC recurrence","HCC resection","Adjuvant therapy","2026-07-14",{"date":222,"type":39},"2026-07-16",{"date":224,"type":21},"2026-07",{"date":226,"type":21},"2028-07",{"name":228,"class":229},"Royan Institute","OTHER_GOV",{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":17,"minAge":89,"maxAge":173,"enrollmentInfo":237,"targetDuration":4,"studyType":59,"phases":238,"briefSummary":239,"conditions":240,"keywords":242,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":81},"100637600","the-effect-of-intradialytic-eye-exercise-in-hemodialysis-patients-100637600","NCT07591714","The Effect of Intradialytic Eye Exercise in Hemodialysis Patients","The Effect of Intradialytic Eye Exercise on Physical Function, Balance, and Fall Risk in Hemodialysis Patients: A Randomized Pilot Trial","Inclusion Criteria\n\n* Adults ≥18 years receiving maintenance in-center hemodialysis\n* Clinically stable for brief seated intradialytic intervention\n* Able to understand and follow eye-exercise instructions\n* Able to provide informed consent\n* Able to sit upright independently during dialysis\n* Able to complete repeated outcome assessments\n* Able to communicate discomfort or adverse symptoms\n* Usual corrective lenses permitted if needed for visual clarity\n\nExclusion Criteria\n\n* Unstable cardiac conditions (e.g., unstable angina, recent myocardial infarction, decompensated heart failure, uncontrolled arrhythmia)\n* Active infection or acute medical illness\n* Hemodynamic instability\n* Significant cognitive or communication impairment preventing instruction-following\n* Severe uncorrected visual impairment or active ocular disease\n* Recent major ophthalmologic surgery\n* Severe musculoskeletal or neurologic limitations preventing participation or testing\n* Any condition deemed unsafe for intradialytic exercise by the treating physician or nephrologist",{"count":108,"type":21},[61],"This pilot randomized trial will evaluate whether a structured intradialytic eye-exercise program can be delivered safely and consistently during maintenance hemodialysis and whether it shows preliminary promise for improving physical function, balance, and fall-related concern. The study is needed because hemodialysis patients commonly experience impaired physical performance, reduced balance, and fear of falling, and these problems are associated with higher fall risk; at the same time, supervised exercise during dialysis is increasingly viewed as a practical way to reach this medically complex and often sedentary population. Eye-movement and gaze-stability training has also shown benefit for balance- and fall-related outcomes in older adults and stroke survivors, but its feasibility and potential value during dialysis sessions remain uncertain.",[241,180],"End Stage Renal Disease",[243,244,245,183,246,247,248],"Eye exercise","Gaze stabilization exercise","Home based exercise","Balance impairment","Fall risk","Physical function","2026-07-02",{"date":251,"type":39},"2026-07-06",{"date":253,"type":39},"2026-06-01",{"date":255,"type":21},"2026-09",{"name":198,"class":46},{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":12,"sex":17,"minAge":89,"maxAge":173,"enrollmentInfo":264,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":266,"conditions":267,"keywords":271,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":285,"locationsCount":81},"100644902","safety-and-effectiveness-evaluation-of-temozolomide-amitzo-nanoalvand-in-patients-with-grade-iii-and-iv-glioma-tumors-100644902","NCT07675070","Safety and Effectiveness Evaluation of Temozolomide (Amitzo, NanoAlvand) in Patients With Grade III and IV Glioma Tumors","A Phase IV and Observational Study to Evaluate Safety and Effectiveness of Temozolomide (Amitzo, NanoAlvand) Therapy in in Patients With Grade III and IV Glioma Tumors","Inclusion Criteria:\n\n* Patients with newly diagnosed grade III or IV glial tumors, or patients who have experienced disease recurrence or progression after receiving standard treatment and, based on the treating physician's diagnosis, require treatment with temozolomide\n* Patients aged 18-80 years old\n\nExclusion Criteria:\n\n* Patients without a baseline MRI\n* Patients who are unwilling to participate in the study",{"count":265,"type":21},100,"This is a phase IV, post-marketing, observational, cohort study for safety and effectiveness evaluation of Amitzo® in Iranian patients with grade III and IV glioma tumors. No control group is considered in the study design. The primary objective is to evaluate the incidence of hepatic injury in patients with grade III and IV glioma tumors, treated with Amitzo®.",[268,269,270],"Brain Tumor","Grade III Glioma","Grade IV Glioma",[272,273,274,275,276,277,278],"Brain Neoplasms","Temozolomide","Effectiveness","Safety","Glioma","Amitzo","Adverse Event","2026-06-23",{"date":281,"type":39},"2026-06-30",{"date":283,"type":39},"2026-03-22",{"date":196,"type":21},{"name":286,"class":287},"NanoAlvand","INDUSTRY",{"id":289,"slug":290,"hasResults":12,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":12,"sex":17,"minAge":295,"maxAge":296,"enrollmentInfo":297,"targetDuration":4,"studyType":59,"phases":298,"briefSummary":300,"conditions":301,"keywords":303,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":315},"100636929","phase-1-safety-and-feasibility-of-bilateral-striatal-transplantation-of-dopacell-in-parkinsons-disease-100636929","NCT07572071","Safety and Feasibility of Bilateral Striatal Transplantation of DopaCell in Parkinson's Disease","Evaluation of the Safety and Feasibility of a Single Transplantation of 10 Million Human Embryonic Stem Cell-Derived Dopaminergic Progenitor Cells Into the Bilateral Striatum of Patients With Moderately Severe Parkinson's Disease: a Multicenter, Open-label, Single-arm Phase I Clinical Trial","Inclusion Criteria:\n\n* Age: 30-70 years\n* Diagnosis of PD: MDS clinical Diagnostic Criteria for Parkinson's disease\n* The disease duration more than 5 years\n* Moderate Parkinson's disease, defined as a Hoehn and Yahr stage of 2 or 3 during the OFF period.\n* The patient is receiving oral pharmacological therapy, and in the opinion of the Principal Investigator, the patient's symptoms remain inadequately controlled despite optimal medical management, or the patient is experiencing adverse effects related to their current treatment\n* No history or only mild levodopa-induced dyskinesia, defined as a score of 2 or less on the UDysRS scale in any body region during the ON state.\n* The patient demonstrates a clinically meaningful response to a therapeutic dose of levodopa, as determined by the Principal Clinical Investigator or a trained specialist under the supervision of the Principal Investigator.\n* The performance of different organs based on laboratory evaluations:\n\n  * Number of neutrophils ≥2000 \u002F microliter\n  * Platelet count ≥100,000 \u002F microliter\n  * AST \u002F ALT: less than or equal to three times the maximum normal value at the intervention site\n  * Total bilirubin less than or equal to 1.5 times the maximum normal amount at the intervention site\n  * eGFR \\* rate: greater than or equal to 60 ml \u002F min \u002F 1.73 m2 \\* eGFR (mL \u002F min \u002F 1.73 m2) = 194 X Cr \\^ -1.094 X age \\^ -0.287 (X 0.739 for females)\n* Informed consent\n\nExclusion Criteria:\n\n* The abnormal function of immune system\n* The symptomatic brain injuries (brain atrophy, cerebral Infarct, trauma, vascular malformation) confirmed by brain MRI\n* Markedly reduced or normal signal in the ventral striatum on TRO-DaT SPECT imaging.\n* Any abnormal findings on brain MRI.\n* Positive GBA mutation test.\n* Diagnosis of dementia based on a MoCA score \\\u003C 24.\n* The abnormality of thrombotic system or high risk of bleeding\n* Positive for any of the following viral markers or active infections: HBsAg, HBsAb, HBcAb, anti-HIV antibodies, anti-HTLV-1\\&2 antibodies, active hepatitis C infection, syphilis, or active CMV, VZV, EBV, or COVID-19 infection.\n* Impossibility of MRI imaging for patients with metal in the body, pacemaker in the body, claustrophobia, with artificial heart valves that are incompatible with MRI or body weight is not within the tolerable range for MRI.\n* Patients with contraindications to the study drug: Tacrolimus, Prednisolone, Basiliximab, Cotrimoxazole, MRI contrast agent.\n* Patients undergoing other cell transplants, including embryonic stem cell-derived dopaminergic progenitor cells.\n* Patients with a history of PD at the same time and concurrent: Malignant neoplasm, epilepsy, cerebral hemorrhage or a positive history\n* Psychiatric disorders confirmed by a psychiatrist, including major depression, bipolar disorder, or schizophrenia, that are uncontrolled or treatment resistant.\n* Patients with intellectual disability who, in the judgment of a psychiatrist, are unable to fully comprehend the study requirements.\n* History of pallidotomy, thalamotomy, or deep brain stimulation (DBS).\n* Patients considered high-risk candidates for surgery, particularly neurosurgery or DBS implantation, due to significant cardiovascular, pulmonary, or other systemic comorbidities identified during preoperative evaluation.\n* Patients who have a history of taking the following in the three months prior to enrollment: Immunosuppressant, antipsychotic drug, anticonvulsant drugs or anticoagulant therapy (if discontinuation or perioperative adjustment is not feasible), botulinum toxin (within 6 months), phenol injections, or other treatments for dystonia or muscle spasm\n* History of Apomorphine use\n* History of chronic alcohol use or illicit drug abuse.\n* Patients who are pregnant, lactating, or people who did not avoid pregnancy during the study.\n* Patients who, according to the researchers' opinions, are not suitable for safe study.","30 Years","70 Years",{"count":207,"type":21},[299],"PHASE1","Dopason is a phase I, open-label, multicenter, single-arm clinical trial designed to evaluate the safety and feasibility of intraputaminal transplantation of human embryonic stem cell-derived dopaminergic progenitor cells (DopaCells) in patients with moderately severe Parkinson's disease.",[302],"Parkinson Disease (PD)",[304,305,306],"Parkinson's disease","Dopaminergic progenitor cell transplantation","Intrastriatal","2026-06-16",{"date":309,"type":39},"2026-06-18",{"date":311,"type":39},"2025-08-01",{"date":313,"type":21},"2030-08-01",{"name":228,"class":229},3,{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":12,"sex":17,"minAge":295,"maxAge":323,"enrollmentInfo":324,"targetDuration":4,"studyType":59,"phases":325,"briefSummary":326,"conditions":327,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":81},"100602413","oregano-and-basil-leaves-and-coronary-artery-disease-100602413","NCT07123181","Oregano and Basil Leaves and Coronary Artery Disease","Effects of Increasing Polyphenol Intake by Consumption of Oregano and Basil Leaves on Plasma Inflammatory and Lipid Factors and Total Urinary Polyphenol in Patients With Unstable Angina","Inclusion Criteria:\n\n* Patients diagnosed with unstable angina\n\nExclusion Criteria:\n\n* Patients diagnosed with STEMI\n* Patients undergoing coronary artery bypass grafting\n* Liver cirrhosis and advanced chronic kidney disease (CKD 5)\n* Having known inflammatory and autoimmune diseases, such as inflammatory bowel disease (IBD) and rheumatoid arthritis, or taking glucocorticoid medications\n* Pregnancy or breastfeeding","75 Years",{"count":153,"type":21},[61],"The present study will examine the effects of increasing dietary polyphenol intake by consumption of oregano and basil leaves, on plasma inflammatory and lipid factors and total urinary polyphenol levels in patients who have recently had unstable angina.",[328,329],"Acute Coronary Syndromes","Unstable Angina (UA)","2026-06-13",{"date":307,"type":39},{"date":333,"type":39},"2025-09-01",{"date":335,"type":21},"2026-10-22",{"name":165,"class":46},{"id":338,"slug":339,"hasResults":12,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":343,"eligibilityCriteria":344,"healthyVolunteers":12,"sex":17,"minAge":89,"maxAge":345,"enrollmentInfo":346,"targetDuration":348,"studyType":22,"phases":4,"briefSummary":349,"conditions":350,"keywords":359,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":375},"100600524","a-new-tool-for-extubation-readiness-in-mechanically-ventilated-patients-readiness-for-extubation-score-100600524","NCT07098611","A New Tool for Extubation Readiness in Mechanically Ventilated Patients: Readiness for EXtubation Score","A New Tool for Extubation Readiness in Mechanically Ventilated Patients: Readiness for EXtubation Score (REXs STUDY)","REXs","Inclusion Criteria:\n\n\\- Patients who are in the weaning process from mechanical ventilation after being connected to invasive mechanical ventilation in the intensive care unit.\n\nExclusion Criteria:\n\n* Patients without legal guardian consent.\n* Tracheostomized patients.\n* Patients enrolled in other studies.\n* Individuals with diaphragmatic pacers.\n* Pregnant patients.","89 Years",{"count":347,"type":21},470,"6 Weeks","Liberation from mechanical ventilation involves three steps: weaning, readiness assessment, and extubation. Readiness is determined using clinical criteria such as improvement of the underlying condition, hemodynamic stability, and adequate respiratory effort. Successful extubation is defined as not requiring invasive support within 48 hours. Due to the complexity of ICU patients, various clinical parameters and multi-component scores have been developed to predict extubation success. This study aims to develop and evaluate a multi-component score, the Readiness for EXtubation score (REXs), to predict extubation readiness in ICU patients under invasive mechanical ventilation.",[351,352,353,354,355,356,357,358],"Ventilator Weaning","Respiration, Artificial","Respiratory Failure","Extubation Readiness","Extubation Failure","Extubation Succeeded","Intensive Care Patients Invasively Ventilated","Weaning Invasive Mechanical Ventilation",[360,361,362,363,364,365],"mechanical ventilation","extubation","weaning","readiness","prediction","score","2026-04-29",{"date":368,"type":39},"2026-05-05",{"date":370,"type":39},"2025-06-15",{"date":372,"type":21},"2026-12-30",{"name":374,"class":46},"Medipol University",7,{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":383,"sex":17,"minAge":89,"maxAge":4,"enrollmentInfo":384,"targetDuration":4,"studyType":59,"phases":386,"briefSummary":387,"conditions":388,"keywords":392,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":81},"100635413","chatgpt-driven-blended-teaching-for-pain-management-in-nursing-students-a-randomized-controlled-trial-100635413","NCT07552363","ChatGPT-Driven Blended Teaching for Pain Management in Nursing Students: A Randomized Controlled Trial","Effect of a ChatGPT-Driven Blended Teaching Model for Pain Management on Knowledge, Attitudes, Competence, and Self-Efficacy Among Nursing Students: A Two-Arm Parallel-Group Randomized Controlled Trial","Inclusion Criteria:\n\n1. Undergraduate nursing students in their fourth semester or higher, or master's or doctoral nursing students engaged in clinical training involving direct patient care\n2. Provision of electronic informed consent\n3. Access to the internet and a personal device (computer, tablet, or smartphone) for the asynchronous components of the blended teaching model\n4. No participation in a formal comprehensive pain management course within the previous 12 months\n\nExclusion Criteria:\n\n1. Inability to attend at least one face-to-face session or to complete online activities (e.g., due to repeated absences)\n2. Any self-reported or university-documented cognitive or mental health condition that prevented completion of questionnaires or participation in training\n3. Voluntary withdrawal at any stage of the study",true,{"count":385,"type":21},156,[61],"Pain management is a core competency in nursing practice, yet nursing students consistently demonstrate insufficient knowledge, unfavorable attitudes, limited competence, and low self-efficacy in this area. Artificial intelligence (AI)-based educational tools, particularly ChatGPT, have emerged as promising resources in nursing education; however, rigorous experimental evidence on their effectiveness remains scarce.\n\nThis study is a two-arm, parallel-group randomized controlled trial (RCT) that aims to evaluate the effect of a ChatGPT-driven blended teaching model for pain management on nursing students' knowledge and attitudes toward pain, nursing competence, and learning self-efficacy.\n\nEligible nursing students at Shahid Beheshti University of Medical Sciences (Tehran, Iran) will be randomly assigned in a 1:1 ratio to either:\n\n* Intervention group: ChatGPT-assisted blended clinical nursing rounds (8 sessions over 4 weeks, each 90 minutes, combining bedside rounds with AI-assisted pre- and post-round activities)\n* Control group: Traditional clinical nursing rounds (same number and duration of sessions, without any AI tools)\n\nOutcomes will be measured at baseline (1 week before intervention), immediate post-test (1 week after intervention), and 3-month follow-up using validated instruments: the Nurses' Knowledge and Attitudes Survey Regarding Pain (NKASRP), the Nursing Student Competence Scale (NSCS), and the Nursing Students' Learning Self-Efficacy instrument (NLSE).\n\nFindings will provide empirical evidence to guide educational policy and curriculum design in nursing programs, with the goal of improving pain management education and patient care outcomes.",[389,390,391],"Pain Management","Nursing Education","Knowledge, Attitudes, Practice",[393,394,395,389,396,397,398],"ChatGPT","Artificial Intelligence","Blended Learning","Nursing Students","Clinical Competence","Randomized Controlled Trial","2026-04-20",{"date":401,"type":39},"2026-04-27",{"date":403,"type":21},"2026-09-01",{"date":405,"type":21},"2027-01-01",{"name":165,"class":46},{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":12,"sex":17,"minAge":89,"maxAge":4,"enrollmentInfo":413,"targetDuration":4,"studyType":59,"phases":415,"briefSummary":416,"conditions":417,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":426,"locationsCount":81},"100614278","the-effect-of-integrating-pain-neuroscience-educationpne-with-conventional-physiotherapy-on-pain-and-functional-disability-in-patients-with-acute-low-back-pain-100614278","NCT07277517","The Effect of Integrating Pain Neuroscience Education(PNE) With Conventional Physiotherapy on Pain and Functional Disability in Patients With Acute Low Back Pain","Inclusion Criteria:\n\n* Adults aged 18 years and older.\n* A primary complaint of acute low back pain (defined as pain between the bottom of the ribs and the gluteal fold), with or without leg pain.\n* Pain duration of less than 6 weeks.\n* Absence of any \"red flags\" for serious spinal pathology (e.g., tumor, infection, fracture, cauda equina syndrome), as confirmed by an orthopedist or neurologist.\n\nExclusion Criteria:\n\n* Low back pain lasting more than 3 months (chronic low back pain).\n* History of spinal surgery within the past 3 years.\n* Inability to read or understand Persian.\n* Diagnosed cognitive impairments.\n* Unwillingness to continue the treatment or study protocol.\n* Diagnosed rheumatic, neurological, cardiac, metabolic, or respiratory diseases.\n* Diagnosis of fibromyalgia, chronic fatigue syndrome, loss of skin sensation, or skin inflammation\u002Fswelling in the low back area.\n* Presence or emergence of any \"red flag\" condition.\n* Missing more than 3 consecutive treatment sessions.\n* Previous participation in Pain Neuroscience Education sessions.",{"count":414,"type":21},48,[61],"Acute low back pain is one of the most common health problems in the world. Most people experience it at least once in their lives, and although many cases improve within a few weeks, a significant number of patients continue to struggle with pain, fear of movement, stress, and reduced daily function. These psychological factors-such as catastrophizing (\"my back is damaged\"), fear of movement (\"if I move, it gets worse\"), and avoidance behaviors-can slow recovery and increase the risk of the pain becoming chronic.\n\nPain Neuroscience Education (PNE) is a modern educational approach that teaches patients how pain actually works in the nervous system. Instead of focusing only on muscles and bones, PNE helps people understand how the brain interprets pain, why pain can persist even without serious injury, and how thoughts, emotions, and behaviors can influence the experience of pain. Research shows that PNE can reduce fear, improve movement, and help people participate better in rehabilitation-especially in chronic pain. However, there is very limited high-quality evidence about its effects in acute low back pain.\n\nThe purpose of this study is to determine whether adding Pain Neuroscience Education to routine physiotherapy can improve recovery in people with acute low back pain.\n\nTo do this, the investigators will conduct a single-blind randomized clinical trial with two groups of patients:\n\nControl group: Receives conventional physiotherapy, including soft-tissue mobilization and TENS, along with routine patient education about posture and back care.\n\nIntervention group: Receives the same physiotherapy plus two structured sessions of Pain Neuroscience Education, delivered individually using simple explanations, metaphors, and visual materials.\n\nBoth groups will receive eight treatment sessions over four weeks.\n\nThe investigators will measure several important outcomes before starting treatment and immediately after the 8th session, including:\n\nPain intensity\n\nFunctional disability\n\nPain catastrophizing\n\nFear-avoidance beliefs\n\nFear of movement (kinesiophobia)\n\nThe investigators' hypothesis is that patients who receive PNE in addition to routine physiotherapy will show greater reductions in pain, disability, fear, and catastrophizing compared to those receiving physiotherapy alone.\n\nIf proven effective, this approach could provide a simple, low-cost, and safe addition to physiotherapy that not only reduces pain but also prevents acute low back pain from turning into a chronic condition. This could help improve patients' quality of life and reduce the economic and healthcare burden caused by low back pain.",[418],"Acute Low-back Pain","2026-03-30",{"date":421,"type":39},"2026-04-03",{"date":423,"type":39},"2025-10-05",{"date":425,"type":21},"2026-08",{"name":427,"class":46},"Iran University of Medical Sciences",{"id":429,"slug":430,"hasResults":12,"nctId":431,"briefTitle":432,"officialTitle":433,"acronym":4,"eligibilityCriteria":434,"healthyVolunteers":12,"sex":17,"minAge":89,"maxAge":4,"enrollmentInfo":435,"targetDuration":4,"studyType":59,"phases":436,"briefSummary":438,"conditions":439,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":447,"locationsCount":81},"100625485","phase-4-tirzepatide-spartina-in-obese-kidney-transplant-recipients-100625485","NCT07423247","Tirzepatide (Spartina) in Obese Kidney Transplant Recipients","Safety and Efficacy of Tirzepatide (Spartina) in Obese Kidney Transplant Recipients: A Pilot Study on Weight Loss, Gastrointestinal Tolerability, and Graft Function","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Kidney transplant recipient with ≥12 months since transplantation\n* BMI ≥ 27 kg\u002Fm²\n* Stable graft function in the last 3 months (serum creatinine variation \\\u003C 20%)\n* Stable immunosuppressive regimen\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* History of pancreatitis\n* Severe gastroparesis\n* History of medullary thyroid carcinoma (MTC) or MEN2 syndrome\n* eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²\n* Acute rejection episode within the past 6 months\n* Any condition judged by the investigator to interfere with study participation or safety",{"count":108,"type":21},[437],"PHASE4","Post-transplant obesity is a common complication after kidney transplantation, largely attributed to recovery from uremia, increased appetite, sedentary lifestyle, and long-term corticosteroid exposure. Obesity in kidney transplant recipients increases the risk of cardiovascular disease, post-transplant diabetes mellitus (PTDM), and may contribute to graft injury through hyperfiltration-related mechanisms, potentially leading to reduced graft survival. Current approaches for weight management in transplant recipients, including lifestyle modification, are often insufficient, while bariatric surgery carries considerable risks and concerns regarding altered absorption of immunosuppressive medications.\n\nTirzepatide (Iranian brand name: Spartina), the first dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has demonstrated superior effects on weight reduction and glycemic control compared with earlier GLP-1 receptor agonists in the general population. However, its use in kidney transplant recipients requires careful evaluation due to potential gastrointestinal adverse effects, dehydration risk, and possible interaction with calcineurin inhibitor absorption caused by delayed gastric emptying.\n\nThis prospective single-arm pilot clinical trial aims to assess the preliminary safety and efficacy of tirzepatide in obese kidney transplant recipients with stable graft function. Outcomes include changes in anthropometric indices, percent weight change, gastrointestinal tolerability, immunosuppressive drug trough levels, and graft function over 24 weeks of treatment.",[440],"Tirzepatide","2026-02-13",{"date":443,"type":39},"2026-02-20",{"date":445,"type":39},"2026-01-01",{"date":255,"type":21},{"name":165,"class":46},{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":4,"eligibilityCriteria":454,"healthyVolunteers":12,"sex":17,"minAge":89,"maxAge":4,"enrollmentInfo":455,"targetDuration":4,"studyType":59,"phases":457,"briefSummary":458,"conditions":459,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":465,"leadSponsor":467,"locationsCount":81},"100593445","treatment-of-chronic-active-antibody-mediated-rejection-with-tocilizumab-100593445","NCT07006532","Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab","Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients With Tocilizumab ,IVIG, Plasmapheresis, Rituximab Versus IVIG, Plasmapheresis , Rituximab","Inclusion Criteria:\n\n1. Signed written informed consent\n2. eGFR\\> 25 cc\u002Fmin\n3. Chronicity index \\\u003C8\n4. IFTA\\\u003C40%\n5. EBV IgG positive\n\nExclusion Criteria:\n\n1. Active or recurrent infections\n2. History of malignancy, unless in remission for more than 2 years with no relapse\n3. abnormal liver function tests\n4. Platelet \\\u003C 100,000",{"count":456,"type":21},50,[61],"Chronic active antibody mediated rejection (CAMR) is a therapeutic challenge in transplant recipients that does not respond well to conventional treatments for acute antibody mediated rejection (AMR). Annually, 5000 kidney transplants are lost in the United States due to CAMR. The two-year graft survival rate in CAMR is approximately 20%, highlighting the need for a more efficient therapy for CAMR and directly targeting donor specific antibody (DSA) producing cells and reducing CAMRThere is no established treatment for this problem. While many centers intensify and optimize the dosage of immunosuppressive drugs, treatments such as plasmapheresis, IVIG, and rituximab, although effective in treating AMR, have not been successful in reducing DSA or improving kidney graft survival in CAMR patients. Despite these treatments, two-year graft survival can increase up to 55%. The use of anti-plasma cell treatments like bortezomib has also yielded inconsistent results.",[460],"Kidney Transplant Rejection","2026-02-08",{"date":463,"type":39},"2026-02-11",{"date":41,"type":39},{"date":466,"type":21},"2027-05-01",{"name":165,"class":46},{"id":469,"slug":470,"hasResults":12,"nctId":471,"briefTitle":472,"officialTitle":473,"acronym":4,"eligibilityCriteria":474,"healthyVolunteers":12,"sex":17,"minAge":89,"maxAge":4,"enrollmentInfo":475,"targetDuration":4,"studyType":59,"phases":476,"briefSummary":477,"conditions":478,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":486,"locationsCount":81},"100619314","conjunctival-transpositional-surgery-for-primary-pterygium-100619314","NCT07343011","Conjunctival Transpositional Surgery for Primary Pterygium","Conjunctival Transpositional Pterygium Surgery: A Prospective Single-Arm Interventional Study","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Primary pterygium involving the cornea\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Recurrent pterygium\n* Previous ocular surface surgery\n* Active ocular infection or inflammation\n* Severe ocular surface disease",{"count":153,"type":21},[61],"This prospective single-arm interventional study evaluates the recurrence rate and functional outcomes following conjunctival transpositional pterygium surgery without bare sclera formation. The technique involves mobilization and transposition of the pterygium tissue while preserving Tenon's layer and avoiding adjunctive therapies.",[479],"Pterygium of the Conjunctiva and Cornea","2026-01-06",{"date":482,"type":39},"2026-01-15",{"date":484,"type":39},"2025-05-21",{"date":405,"type":21},{"name":487,"class":46},"Zahedan University of Medical Sciences",{"id":489,"slug":490,"hasResults":12,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":4,"eligibilityCriteria":494,"healthyVolunteers":12,"sex":495,"minAge":496,"maxAge":497,"enrollmentInfo":498,"targetDuration":4,"studyType":59,"phases":500,"briefSummary":501,"conditions":502,"keywords":504,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":517,"locationsCount":81},"100615896","effect-of-magnesium-and-levocarnitine-on-metabolic-and-clinical-outcomes-in-women-with-polycystic-ovarian-syndrome-pcos-100615896","NCT07298564","Effect of Magnesium and Levocarnitine on Metabolic and Clinical Outcomes in Women With Polycystic Ovarian Syndrome (PCOS)","Assessment of the Effect of Magnesium and Levocarnitine Co-supplementation on Lipid Profile, Glycemic Control Indicators and Hirsutism in Women With Polycystic Ovarian Syndrome","Inclusion Criteria:\n\n* Age between 19 and 65 years.\n* Diagnosis of polycystic ovary syndrome (PCOS) according to the Rotterdam criteria.\n\nExclusion Criteria:\n\n* Hypothyroidism\n* Menopause\n* Pregnancy or breastfeeding\n* Renal (kidney) dysfunction\n* Use of therapeutic vitamin or mineral supplements\n* Liver diseases (e.g., grade 3 fatty liver, hepatitis, or cirrhosis)\n* Psychiatric disorders such as bipolar disorder\n* Neuromuscular diseases (e.g., myasthenia gravis, Parkinson's disease, multiple sclerosis, epilepsy, or muscular dystrophy)\n* History of seizures\n* Participants who become pregnant during the study or fail to comply with more than 20% of the study protocol will be withdrawn from the study","FEMALE","19 Years","65 Years",{"count":499,"type":21},84,[61],"Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age and is associated with metabolic abnormalities such as insulin resistance, dyslipidemia, and hormonal imbalance, which may lead to infertility and hirsutism. Despite the availability of several pharmacological treatments, many therapies fail to effectively address the underlying metabolic and endocrine dysfunctions of PCOS. Magnesium and L-carnitine are two essential nutrients that may play a synergistic role in improving insulin sensitivity, glucose metabolism, and lipid profile, as well as reducing oxidative stress and androgen production in women with PCOS. This randomized, triple-blind, placebo-controlled clinical trial aims to evaluate the effects of co-supplementation with magnesium and L-carnitine on glycemic control indices, lipid profile, and hirsutism in women with PCOS. A total of 84 eligible women aged 19-65 years diagnosed with PCOS according to the Rotterdam criteria will be recruited from Shohada Tajrish Hospital, Tehran, Iran. Participants will be randomly assigned to one of three groups: (1) magnesium supplementation (500 mg\u002Fday, in two 250 mg doses) plus L-carnitine placebo, (2) L-carnitine supplementation (1000 mg\u002Fday) plus magnesium (500 mg\u002Fday), or (3) placebo control group. The intervention period will last 12 weeks. Physical activity information will be collected using short form of International Physical Activity Questionnaire (IPAQ) and demographic information through a general information questionnaire. In order to evaluate dietary intake of patients in terms of energy(kcal\u002F(day), carbohydrate(gr\u002Fday), protein(gr\u002Fday), fat intake(gr\u002Fday), saturated fatty acids (SFA) (gr\u002Fday), monounsaturated fatty acids (MUFA) (gr\u002Fday), polyunsaturated fatty acids (PUFA)(gr\u002Fday), Vitamin E (mg\u002Fday), Vitamin C (mg\u002Fday), Beta-carotene (mg\u002Fday) and Vitamin A (mg\u002Fday), cupper intake (mg\u002Fday), selenium intake (mg\u002Fday), and zink intake (mg\u002Fday), 24-hr recalls will be completed by interviewing the patient for 3 days (two normal days and a weekend day). Weight will be measured with the minimum dress and without shoes by using a digital balance scale of 100 grams and height will be measured without shoes by meters mounted to the wall with an accuracy of 0.5 centimeters. Then the body mass index will be calculated by dividing the weight (kg) by the square of the height (m), waist circumference will be measured in the narrowest area between the lowest lumbar spine and the iliac bone (cm), systolic and diastolic blood pressure will be measured after 15 minutes of rest, twice using the mercuric barometric measure and the mean will be reported as individual blood pressure. The blood sample will be taken after 12 hours of overnight fasting in three groups for measuring Fasting Blood Sugar (FBS) (mg\u002FdL), lipid profile (mg\u002FdL), Hemoglobin A1c (HbA1C) (percentage), serum insulin concentration (µIU\u002Fml) and insulin resistance. Insulin resistance will be calculated using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) formula, and hirsutism score (using the modified Ferriman-Gallwey method) will be assessed at baseline and post-intervention. At the end of the study, counting the remaining capsules, the patient's compliance rate will be evaluated, and patients who have consumed less than 90% of their capsules will be excluded from the analysis.",[503],"Polycystic Ovary Syndrome (PCOS)",[505,506,507,508,509],"Polycystic Ovary Syndrome","Hyperandrogenism","Insulin Resistance","Dyslipidemia","Hirsutism","2025-12-22",{"date":512,"type":39},"2025-12-23",{"date":514,"type":21},"2026-01-30",{"date":516,"type":21},"2026-11-30",{"name":518,"class":46},"Behnood Abbasi",{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":525,"eligibilityCriteria":526,"healthyVolunteers":12,"sex":54,"minAge":89,"maxAge":296,"enrollmentInfo":527,"targetDuration":4,"studyType":59,"phases":528,"briefSummary":530,"conditions":531,"keywords":538,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":542,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":547,"locationsCount":81},"100617508","phase-2-clinical-trial-investigating-the-effect-of-exosomes-as-a-complementary-treatment-in-severe-to-moderate-erectile-dysfunction-100617508","NCT07319533","Clinical Trial Investigating the Effect of Exosomes as a Complementary Treatment in Severe to Moderate Erectile Dysfunction","Investigating the Effect of Exosome Derived From Human Fetal Umbilical Cord Mesanchymal Cells as Complimintary Treatment in Moderate to Severe Erectile Dysfunction","MSC","Inclusion Criteria:\n\nModerate or severe erectile dysfunction (according to IIEF-5) Non-satisfactory response to other treatments Generally Healthy males Not having severe past medical history\n\nExclusion Criteria:\n\nKnown allergy or history of hyperactivity to biological substances Peyronie's plaque Existing medical condition (severe or uncontrolled) Use of psychiatric medication Use of thyroid medication Hyopgonadism Hypergonadism Cancer History of prostatectomy Prostitis Autoimmune disease Recent trauma or surgery Ongoing systemic infection Skin lesion or infection at the site of injection",{"count":153,"type":21},[529],"PHASE2","The goal of this clinical trial is to Investigate the Effect of Injection of MSC-Derived Exosome on Patients with Erectile Dysfunction in overall healthy males, aged 18-70, with-out any severe active medical condition, with moderate to severe erectile dysfunction based on IIEF-5, and non-satisfactory response to other treatments (5PDEI). The main question it aims to answer is:\n\n• Is MSC-derived exosome safe and effective in treating patients with ED by improving IIEF-5 score?\n\nIf there is a comparison group: Researchers will compare the intervention group (Exosome receiving group) with control group (placebo receiving group) to see if exosomes are safe and effective in treating male adult patients with moderate-sever ED.\n\nParticipants will receive six weekly injections of normal saline or exosome (based on group), and will undergo necessarily follow up, and examinations and observation.",[532,533,534,535,536,537],"Erectile Dysfunction","Erectile Dysfunction Associated With Type 2 Diabetes Mellitus","Erectile Dysfunction Due to Arterial Disease","Erectile Dysfunction Due to Arterial Insufficiency","Erectile Dysfunction Due to General Medical Condition","Erectile Dysfunction Due to Neuropathy",[532,539,540,525],"Exosome","Mesanchymal Stem Cell","2025-12-21",{"date":480,"type":39},{"date":544,"type":21},"2026-01",{"date":546,"type":21},"2027-01",{"name":548,"class":46},"Labbafinejad Medical Center",{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":4,"eligibilityCriteria":555,"healthyVolunteers":12,"sex":17,"minAge":556,"maxAge":89,"enrollmentInfo":557,"targetDuration":4,"studyType":59,"phases":559,"briefSummary":560,"conditions":561,"keywords":563,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":574,"locationsCount":81},"100572756","topical-5-fluorouracil-5fu-plus-calcipotriol-in-children-with-palmoplantar-wart-100572756","NCT06737406","Topical 5-Fluorouracil (5FU) Plus Calcipotriol in Children With Palmoplantar Wart","Efficacy and Safety of 5-Fluorouracil (5FU) in Combination With Calcipotriol in Children (Aged 4 to 18 Years) With Palmoplantar Wart: Double-blind, Placebo-controlled, Randomized Trial","Inclusion Criteria: The inclusion criteria include the clinical or pathological diagnosis (only for suspicious lesions confirmed pathologically) of cutaneous warts on the palmoplantar area by a dermatologist. The patients' ages range from 4 to 18 years old, and the number of warts must be a maximum of 20.\n\nExclusion Criteria: The exclusion criteria include pregnancy and breastfeeding, warts on the face, inguinal, and genital areas, hypersensitivity to topical vitamin D derivatives or fluorouracil, extensive warts requiring other treatments, and receiving any treatment in the past two months. Patients with confirmed immunodeficiency will also be excluded from the study.","4 Years",{"count":558,"type":21},60,[61],"Warts caused by the human papillomavirus (HPV) are one of the most common skin conditions among children. The prevalence of warts in school-aged children ranges from 10 to 20 percent. Warts are more common among immunocompromised patients \\[1, 2\\]. Some studies also show that the prevalence of viral warts in the pediatric population increases with age, peaking in adolescence. HPV is a DNA virus that replicates only in fully differentiated epithelial cells. More than 80 types of HPV have been identified. Types 27, 57, 2, and 1 are the most common types of HPV in skin warts in the general population. Warts usually affect patients of different age groups and various parts of the body, causing physical and psychological complications for patients (such as pain, discomfort, and embarrassment), which in turn lead to functional impairment. Warts often affect pressure points on the soles of the feet. Although most warts are asymptomatic, plantar warts are often associated with pain while walking, causing physical and psychological stress \\[3\\].\n\nVarious treatments such as keratolytic agents, cryotherapy, laser, antimitotic treatments, contact sensitizers, and intralesional injection of antigen have been used. There is no evidence that one treatment is superior to others, and in many cases, treatment of viral warts requires a combination of treatments. Treatment selection for patients should be based on variables such as wart size, number of lesions, anatomical location, patient preference, cost, convenience, side effects, and operator experience. It is important to emphasize that good communication between the patient, parents, and dermatologist is essential for successful treatment in children \\[2, 4\\].\n\nDespite having various treatment approaches, treating plantar warts is challenging. No single treatment is effective in most patients, treatments are often painful, and they are associated with a high recurrence rate. Although nearly 75 percent of warts can resolve spontaneously within two years, patients often seek treatment for cosmetic reasons and pain. Many studies have examined the use of vitamin D compounds (calcipotriol) and 5-fluorouracil in wart patients separately or in combination with other drugs, but only one recent case report that tested the combination of these two showed very positive efficacy results \\[5, 6\\].\n\nTo date, no clinical trial has evaluated the combination of calcipotriol and 5-fluorouracil. Additionally, given that common current treatments such as cryotherapy are painful for children, achieving an effective, pain-free intervention is necessary. This study aims to evaluate the efficacy and side effects of the combination of 5-fluorouracil and calcipotriol in children (ages 4 to 18) with palmar and plantar warts in a randomized, double-blind, placebo-controlled clinical trial.",[562],"Common Warts",[564,565,566,70],"Wart","5-Fluorouracil","Calcipotriol","2025-12-12",{"date":569,"type":39},"2025-12-19",{"date":571,"type":39},"2025-05-30",{"date":573,"type":21},"2026-08-01",{"name":575,"class":46},"Mazandaran University of Medical Sciences",{"id":577,"slug":578,"hasResults":12,"nctId":579,"briefTitle":580,"officialTitle":581,"acronym":440,"eligibilityCriteria":582,"healthyVolunteers":12,"sex":17,"minAge":89,"maxAge":4,"enrollmentInfo":583,"targetDuration":4,"studyType":59,"phases":585,"briefSummary":586,"conditions":587,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":589,"lastUpdatePostDateStruct":590,"startDateStruct":592,"completionDateStruct":594,"leadSponsor":596,"locationsCount":81},"100606523","efficacy-and-safety-of-tirzepatide-spartina-in-chronic-kidney-failure-100606523","NCT07176663","Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure","Safety and Effectiveness of Tirzepatide(Spartina )in Chronic Kidney Failure a Single-center Study","Inclusion Criteria:\n\nage ≥18 years and history of diabetes or BMI over 27\n\nExclusion Criteria:\n\nPrevious usage of similar therapy for less than 3 months owing to the inability to capture all efficacy and safety endpoints within this brief timeframe and\u002For nonadherence to tirzepatide therapy",{"count":584,"type":21},15,[61],"Diabetes management presents a complex clinical scenario marked by several challenges, especially in chronic kidney failure. These include navigating potential drug interactions between oral antidiabetic therapies and other agents. Furthermore, these patients may experience various adverse drug effects, such as lactic acidosis, electrolyte abnormalities such as hypomagnesemia, fluid retention, and lipid derangements, which can further augment overall morbidity. Consequently, many patients receive insulin. However, prolonged intensive insulin therapy may be linked to several adverse outcomes, including an increased risk of hypoglycemia and weight gain.\n\nHence, a common practice is to transition to medications commonly used other populations of patients. With their established benefits on glycemic control, cardiovascular health, renal benefits, and weight management, in conjunction with the aforementioned adverse effects associated with other oral antidiabetics agents, glucagon-like peptide-1 receptor agonists have emerged as an attractive therapeutic option for patients with kidney failure.",[588],"Obesity","2025-12-06",{"date":591,"type":39},"2025-12-15",{"date":593,"type":21},"2026-02-01",{"date":595,"type":21},"2026-05-01",{"name":165,"class":46},{"id":598,"slug":599,"hasResults":12,"nctId":600,"briefTitle":601,"officialTitle":602,"acronym":603,"eligibilityCriteria":604,"healthyVolunteers":12,"sex":495,"minAge":89,"maxAge":4,"enrollmentInfo":605,"targetDuration":4,"studyType":59,"phases":607,"briefSummary":608,"conditions":609,"keywords":614,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":624,"lastUpdatePostDateStruct":625,"startDateStruct":627,"completionDateStruct":628,"leadSponsor":630,"locationsCount":375},"100612487","phase-4-rosuvastatin-for-prevention-of-anthracycline-induced-cardiac-dysfunction-in-breast-cancer-patients-100612487","NCT07254221","Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients","Evaluation of Rosuvastatin Efficacy in Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients After Chemotherapy","ROSUBREAST","Inclusion Criteria:\n\n* Female individuals with ≥18 years of age\n* Documented breast cancer diagnosis based on imaging and pathology findings\n* Scheduled to receive the first time anthracycline-based chemotherapy\n\nExclusion Criteria:\n\n* Baseline LVEF \\\u003C 50%\n* Prior Statin use or Statin use is indicated based on guidelines\n* history of congestive heart failure (CHF) or cardiomyopathy\n* Pregnancy or breastfeeding\n* Unable to provide informed consent\n* Unexplained persistent elevation of transaminases (\\>3 times upper limits of normal)\n* Concomitant use of oral cyclosporine\n* Metastatic invasion of cancer to other organs\n* Previous cycles of chemotherapy\n* Any contraindication for statin use",{"count":606,"type":21},400,[437],"This study, called \"ROSUBREAST\", is a multicenter, double-blind, randomized clinical trial evaluating whether rosuvastatin (20 mg daily) can protect the heart in women with breast cancer receiving anthracycline-based chemotherapy. A total of 400 participants will be randomly assigned to receive either rosuvastatin or placebo for 12 months. The main goal is to determine whether rosuvastatin can prevent cancer treatment-related cardiac dysfunction (CTRCD), defined as a significant drop in heart pumping function. The study will also assess changes in cardiac strain, blood biomarkers, symptoms of heart failure, quality of life, and possible side effects.",[610,611,612,613],"Anthracycline-induced Cardiac Toxicity","Breast Cancer","Anthracycline Related Cardiotoxicity in Breast Cancer","Anthracycline-induced Cardiotoxicity",[615,616,617,618,619,620,621,622,623],"Breast cancer","rosuvastatin","statin therapy,","cancer-related treatment cardiac dysfunction","anthracycline induced cardiomyopathy","cardiac dysfunction","cardiotoxicity","chemotherapy","anthracycline","2025-12-03",{"date":626,"type":39},"2025-12-10",{"date":593,"type":21},{"date":629,"type":21},"2028-04-21",{"name":631,"class":46},"Shiraz University of Medical Sciences",{"id":633,"slug":634,"hasResults":12,"nctId":635,"briefTitle":636,"officialTitle":637,"acronym":4,"eligibilityCriteria":638,"healthyVolunteers":12,"sex":17,"minAge":89,"maxAge":173,"enrollmentInfo":639,"targetDuration":4,"studyType":59,"phases":641,"briefSummary":642,"conditions":643,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":647,"lastUpdatePostDateStruct":648,"startDateStruct":650,"completionDateStruct":652,"leadSponsor":654,"locationsCount":81},"100540054","phase-1-transarterial-chemoembolization-tace-plus-bevacizumab-for-liver-metastases-100540054","NCT06311851","Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases","An Open-Label Pilot Study to Evaluate Efficacy and Safety of Bevacizumab Via Transarterial Chemoembolization (TACE) in Patients With Liver Metastases","Inclusion Criteria:\n\n* Confirmation of metastatic liver cancer via histological examination or a characteristic imaging profile on dynamic computed tomography (CT) scan or magnetic resonance imaging (MRI) without indications for surgical resection\n* Eastern cooperative oncology group performance status (ECOGPS) of 0 or 1\n* Liver function categorized as Child-Pugh class A or B\n* Stable non-hepatic metastases, such as skeletal, pulmonary, or lymph node metastases\n* Hepatic tumor burden below 70%\n* Expected survival duration exceeding six months\n* Laboratory findings meeting specific criteria, including platelet count \\>50×109 \u002FL, hemoglobin \\>8.0 g\u002FdL, ANC count ≥1.5 × 109\u002FL, bilirubin \\\u003C51 mmol\u002FL, alanine and aspartate aminotransferase \\\u003C3 times the upper limit of the normal range, and serum creatinine \\\u003C1.5 times the upper limit of the normal range.\n\nExclusion Criteria:\n\n* Active infection\n* Presence of severe comorbidities, such as hepatic encephalopathy, refractory ascites, and esophageal variceal bleeding\n* Prior liver resection\n* Previous TACE therapy received at other healthcare facilities\n* Poor performance status (ECOGPS \\> 1)",{"count":640,"type":21},40,[299,529],"Trans arterial chemoembolization (TACE) has emerged as a treatment option for chemotherapy-refractory diseases in Liver metastases. By delivering chemotherapy agents directly to the tumor site, TACE can maximize local drug concentrations and reduce systemic adverse reactions. Bevacizumab is a monoclonal antibody that functions as an angiogenesis inhibitor. It works by slowing the growth of new blood vessels by inhibiting vascular endothelial growth factor A (VEGF-A). The application of Bevacizumab during TACE has not been reported. In this study, we will evaluate the the overall survival (OS)、efficacy, and safety of the application of Bevacizumab during TACE in patients with Liver Metastases by designing an open, single-arm phase II clinical study.",[644,645,646],"Cancer","Metastatic Cancer","Liver Metastases","2025-11-23",{"date":649,"type":39},"2025-11-25",{"date":651,"type":39},"2025-06-01",{"date":653,"type":21},"2026-04-30",{"name":655,"class":46},"Pardis Noor Medical Imaging and Cancer Center",{"id":657,"slug":658,"hasResults":12,"nctId":659,"briefTitle":660,"officialTitle":661,"acronym":4,"eligibilityCriteria":662,"healthyVolunteers":12,"sex":17,"minAge":92,"maxAge":663,"enrollmentInfo":664,"targetDuration":4,"studyType":59,"phases":666,"briefSummary":667,"conditions":668,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":671,"lastUpdatePostDateStruct":672,"startDateStruct":674,"completionDateStruct":676,"leadSponsor":678,"locationsCount":81},"100610641","phase-1-effect-of-evfv-on-wound-healing-in-dystrophic-epidermolysis-bullosa-100610641","NCT07230223","Effect of Ev.FV on Wound Healing in Dystrophic Epidermolysis Bullosa","Safety and Efficacy of Ev.FV in Epidermolysis Bullosa Patients, A Randomized Clinical Trial, Phase 1 , 2","Inclusion Criteria:\n\n* DEB participants determined by electron microscopy, or genetic testing. Individuals with severe DEB (eg, RDEB patients with an absence of collagen VII) and milder forms of DEB (eg, RDEB patients with reduced levels of collagen VII) will be eligible.\n* People with one or more active wounds (each between 10 and 50 square centimeters on the arms, legs or trunk.)\n* Participants must be willing to comply with the requirements of the protocol and have consent to participate in the project.\n* Participants must be negative in the urine drug screening visit.\n\nExclusion Criteria:\n\n* Participants with clinical evidence of systemic infection.\n* Participants have a history of bone marrow transplantation.\n* Participants must have evidence of autoimmune disease, including insulin-dependent diabetes.\n* Participant has evidence of significant wound healing prior to treatment (ie, wound closure ≥ 20% during treatment at the first observation period).\n* Participant has a severe medical condition, such as malignancy (including skin cancer), life expectancy less than 2 years, which limits movement to the clinical center.\n* Participants have a current history of alcohol or substance abuse or a history of alcohol or substance abuse that requires treatment in the past 12 months.\n* People participating in the screening should have a positive hepatitis and human immunodeficiency virus (HIV) test result.\n* Women who are pregnant, lactating or planning to become pregnant during the study\n* Women who are of reproductive age and use birth control pills.","35 Years",{"count":665,"type":21},20,[299,529],"Epidermolysis bullosa (EB) is a hereditary disease of skin tissues that causes painful bleeding blisters in the skin and mucous membrane. The prevalence of this disease is 1 in 50,000. The severity of the disease varies depending on the type of disease and may even lead to death. This disease is caused by a genetic mutation in keratin or collagen, and its incidence is the same in all men and women of different human races. In these patients, the skin becomes extremely fragile and peels off with the slightest scratch. Many blisters are one of the most obvious symptoms of this disease. The possibility of skin cancer in people suffering from this disease is more than others.\n\nNowadays, the preference of cell therapy methods is to use biological products produced by cells such as extracellular vesicles and mitochondria instead of stem cells. The use of Extracellular vesicles and engineered EVs as messenger carriers can introduce a new treatment method based on cell products for skin regeneration and as an alternative to cell therapy.\n\nTherefore, in this study, EV.FV will be applied topically to patients.",[669,670],"Dystrophic Epidermolysis Bullosa","Wound Heal","2025-11-14",{"date":673,"type":39},"2025-11-17",{"date":675,"type":39},"2024-01-09",{"date":677,"type":21},"2026-12-25",{"name":679,"class":46},"Isfahan University of Medical Sciences",{"id":681,"slug":682,"hasResults":12,"nctId":683,"briefTitle":684,"officialTitle":684,"acronym":685,"eligibilityCriteria":686,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":687,"targetDuration":92,"studyType":22,"phases":4,"briefSummary":689,"conditions":690,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":692,"lastUpdatePostDateStruct":693,"startDateStruct":695,"completionDateStruct":697,"leadSponsor":699,"locationsCount":701},"100272903","computerized-registry-of-patients-with-venous-thromboembolism-riete-100272903","NCT02832245","Computerized Registry of Patients With Venous Thromboembolism (RIETE)","RIETE","Inclusion Criteria:\n\n* Confirmed VTE (acute deep-vein thrombosis, pulmonary embolism and\u002For superficial venous thrombosis) by objective tests.\n* Informed consent to the participation in the study, according to the requirements of the ethics committee within each hospital.\n\nExclusion Criteria:\n\n* Participation in a therapeutic clinical trial with an unknown drug.\n* Inability to the 3 month follow-up",{"count":688,"type":21},120000,"The Computerized Registry of Patients with Venous Thromboembolism (RIETE) is a multidisciplinary Project initiated in march 2001 and consisting in obtaining an extensive data registry of consecutive patients with venous thromboembolism.\n\nThe main objective is to provide information on the Internet to help physicians to improve their knowledge on the natural history of thromboembolic disease, particularly in those subgroups of patients who are usually not recruited in randomized clinical trials (pregnant women, elderly patients, disseminated cancer, severe renal insufficiency, patients with contraindications to anticoagulation therapy, extreme body weight, etc), with the purpose of decreasing mortality, frequency of thromboembolic recurrences as well as bleeding complications and arterial events.\n\nAs an additional objective RIETE is also aimed to create predictive scores that help physicians to better identify patients with high risk of presenting some of these complications.\n\nThe primary parameters recorded by the registry comprise details of each patient's clinical status, including any coexisting or underlying conditions, and the type, dose, duration and outcome (during the first 3 months of therapy) of antithrombotic treatment. Study endpoints are clinically recognized (and objectively confirmed) recurrences of VTE, major and minor bleeding complications, and death.",[691],"Venous Thromboembolism","2025-09-23",{"date":694,"type":39},"2025-09-24",{"date":696,"type":4},"2001-03",{"date":698,"type":21},"2027-12",{"name":700,"class":46},"Manuel Monreal",257,""]